$Ex \bullet IT B$

Geneseq Database Search Tool

Geneseq Version: 79.0, Release Date: 7Mar2003

```
!!NA_SEQUENCE 1.0
ID    AAW58391 standard; Protein; 285 AA.
AC    AAW58391;
DT    11-SEP-1998   (first entry)
DE    Homo sapiens neutrokine alpha protein.
KW    neutrokine alpha; cell proliferation; differentiation; migration;
KW    cytotoxicity;cell death;. treatment; tumour; infection; inflammation;
KW    wound healing;· immunodeficiency; autoimmune disease; graft rejection;
KW    fibrotic disorder; haematopoiesis; sepsis; shock; malaria; HIV; AIDS;
KW    acquired immune deficiency syndrome; rheumatoid arthritis; silicosis;
KW    cachexia; detection; diagnosis; drug screening.;
OS    Homo sapiens.
FH    Key            Location/Qualifiers
FT    Domain         1. .46
FT                   /note= intracellular domain
FT    Domain         47. .72
FT                   /note= transmembrane domain
FT    Domain         73. .285
FT                   /note= extracellular domain
PN    WO9818921-A1.
PD    07-MAY-1998.
PF    25-OCT-1996;    96WO-US17957.
PR    25-OCT-1996;    96WO-US17957.
PA    (HUMA-) HUMAN GENOME SCI INC.
PI    Ebner R,  Ni J,  Yu G;
DR    WPI; 1998-272216/24.
DR    N-PSDB; AAV30934.
PT    New isolated human Neutrokine alpha - used to develop products for
PT    diagnosis and treatment of e.g. tumours, infections,
PT    immunodeficiencies or autoimmune diseases
PS    Claim 17; Fig 1; 104pp; English.
CC    The sequence is that of the neutrokine alpha protein.
CC    Neutrokine alpha (NA) polypeptides modulate cell proliferation,
CC    differentiation, migration, cytotoxicity and cell death.
CC    They can be used to treat e.g. tumour and tumour metastasis, infections
CC    by bacteria, viruses and other parasites, immunodeficiencies,
CC    inflammatory diseases, lymphadenopathy, autoimmune diseases, graft
CC    versus host disease and to stimulate peripheral tolerance, destroy some
CC    transformed cell lines, mediate cell activation and proliferation, and
CC    are functionally linked as primary mediators of immune regulation and
CC    inflammatory responses.  Such activity is useful for immune enhancement
CC    or suppression, myeloprotection, stem cell mobilisation, acute and
CC    chronic inflammatory control and treatment of leukaemia.  They can also
CC    be used to stimulate wound healing and to treat fibrotic disorders
CC    including liver cirrhosis, osteoarthritis and pulmonary fibrosis. They
CC    can also be used to regulate haematopoiesis, by regulating the activation
CC    and differentiation of various haematopoietic progenitor cells, e.g. to
CC    release mature leukocytes from the bone marrow following chemotherapy,
CC    and in stem cell mobilisation.  NA may also be used to treat sepsis.  NA
CC    antagonists can be used to prevent septic shock, inflammation, cerebral
CC    malaria, activation of the HIV virus, graft-host rejection, bone
CC    resorption, rheumatoid arthritis and cachexia (wasting or malnutrition).
CC    They can also be used to treat e.g. autoimmune diseases such as multiple
CC    sclerosis and insulin-dependent diabetes and inflammatory and infectious
CC    diseases such as silicosis, and sarcoidosis, idiopathic pulmonary
CC    fibrosis, idiopathic hyper-eosinophilic syndrome, endotoxic shock,
CC    atherosclerosis, histamine-mediated allergic reactions and immunological
CC    disorders including late phase allergic reactions, chronic urticaria, and
CC    atopic dermatitis by inhibiting chemokine-induced mast cell and basophil
CC    degranulation and release of histamine.  IgE-mediated allergic reactions
CC    such as allergic asthma, rhinitis and eczema, inflammatory pulmonary
CC    diseases, rheumatoid arthritis, inflammation, degenerative and
CC    inflammatory arthropathies, aplastic anaemia, myelodysplastic syndrome,
CC    subepithelial basement membrane fibrosis or adult respiratory distress
CC    syndrome. The products can also be used for detection, diagnosis and
CC    drug screening.
```

SQ   Sequence   285 AA;

AAW58391 Length: 285 March 11, 2003 16:49 Type: N Check: 5261 ..

```
     1  MDDSTEREQS RLTSCLKKRE EMKLKECVSI LPRKESPSVR SSKDGKLLAA

    51  TLLLALLSCC LTVVSFYQVA ALQGDLASLR AELQGHHAEK LPAGAGAPKA

   101  GLEEAPAVTA GLKIFEPPAP GEGNSSQNSR NKRAVQGPEE TVTQDCLQLI

   151  ADSETPTIQK GSYTFVPWLL SFKRGSALEE KENKILVKET GYFFIYGQVL

   201  YTDKTYAMGH LIQRKKVHVF GDELSLVTLF RCIQNMPETL PNNSCYSAGI

   251  AKLEEGDELQ LAIPRENAQI SLDGDVTFFG ALKLL
```

Blast this sequence